MDGL: Rezdiffra sales rose 50% YoY as profitability began and F4c development advanced

What happened

Rezdiffra generated $431.3M in 3Q26 sales, up 50% year over year, and drove the company's first profitable quarter with $55.4M net income. U.S. MASH market expansion and planned F4c trials support the growth outlook.

Confirmed

Global impact / market context

Reaching profitability means Rezdiffra's sales now cover the company's costs, reducing reliance on outside funding. Planned F4c trials, testing the drug in more advanced liver disease, could widen the patient pool and add future revenue if results succeed.

Analyst inference

The 50% yearly sales growth shows strong demand as the U.S. MASH market expands, a liver disease area with limited approved treatments. Investors will weigh whether profit can persist against the added costs of running the planned F4c trials.

Analyst inference

What to watch

1. Watch whether Rezdiffra sales keep growing at a similar yearly pace in coming quarters, since the 50% increase drove this first profitable quarter. Confirmed
2. Track progress on the planned F4c trials, which would test Rezdiffra in more advanced liver disease and could expand the eligible patient group. Proposed
3. Monitor whether the company sustains net income of $55.4M or more, as trial spending and U.S. MASH market expansion costs could pressure future profits. Analyst inference

Evidence

• Original source link unavailable